

China, Korea lead Asian clinical trials

October 9, 2015 | Analysis | By BioSpectrum Bureau

China, Korea lead Asian clinical trials



According to market report published by Persistence Market Research "Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019" the global clinical trial management system market was valued at USD 844 million in 2013 and is expected to grow at a CAGR of 14 percent from 2014 to 2019, to reach an estimated value of USD 1848.5 million in 2019.

By August 2015, total number of ongoing clinical trials registered at ClinicalTrials.gov, an international body that maintains record of registered clinical trials, clocked 196811 out of which 89819, around 46 percent, are performed in non-US countries.

China recorded the highest number of clinical trials in Asia marking 6501 registered clinical trials, running slightly ahead of Korea that continues to attract majority of clinical trials in east. Diseases getting significant attention in China include digestive system neoplasms that attracted 705 studies, metabolic diseases have 379 current ongoing studies, 364 studies in central nervous system disorders, 352 studies for adenocarcinoma. Arterial occlusive diseases, atherosclerosis and non-small-cell lung cancer are other diseases on which pharmaceutical companies and CROs are investing on in China.

Korea recorded 6483 trials by August 2015 followed by Australia that registered 4801 trials and Taiwan clocked 4062 trials. Clinical research companies in Korea are performing 916 studies on gastrointestinal diseases and 528 studies on gastrointestinal neoplasms. 463 studies are being done on communicable diseases and endocrine System diseases and 316 studies on central nervous system disorders. Arthritis, autoimmune diseases and brain diseases are other major areas of focus for clinical studies.

Australia's significant focus is on cancer as 336 trials are being done on carcinoma. Besides, major studies include 298 studies in central nervous system diseases, 213 studies on children's interstitial lung disease, 269 trials in diabetes mellitus and 246 studies in hematologic diseases. 136 studies have been undertaken in acquired immunodeficiency syndrome diseases.

Though a small nation Taiwan has undertaken 472 studies in communicable diseases and 439 trials in respiratory tract diseases. Other diseases on which clinical research studies have been undertaken include metabolic diseases that has

attracted 318 trials, 297 studies in endocrine system diseases and carcinoma, 305 studies in central nervous system diseases and 279 studies in mental disorders.

Despite having huge population size, India registered just 2688 clinical trials running ahead of Hong Kong that recorded 1101 trials. South East Asia in total registered 40126 trials that included 1760 in Thailand, 1485 in Singapore, 780 in Malaysia and 747 in Philippines.

India has registered 287 studies for glucose metabolism disorders, 269 studies for diabetes mellitus type 2, 263 trials for digestive system diseases, 168 clinical trials for central nervous system diseases, 161 studies in children's interstitial lung disease and 156 trials for skin diseases.